Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05638-7 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Ingo Schwaner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Onkologische Schwerpunktpraxis Kurfuerstendamm, Kurfuerstendamm 65, 10707, Berlin, Germany. ingo.schwaner@onkologie-kurfuerstendamm.de. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Deutschland.
Abstract (Originalsprache)
Venetoclax is active in both frontline and relapsed/refractory settings for the treatment of chronic lymphocytic leukemia (CLL). Although the prevalence and severity of tumor lysis syndrome (TLS) are well characterized in clinical trials, laboratory and clinical TLS remain relatively unexplored in real-world clinical practice. In this prospective, real-world observational study, we aimed to determine the incidence and outcomes of TLS in patients with CLL receiving venetoclax outside a clinical trial. The study (VeRVe) was conducted in centers in Austria, Germany, and Switzerland. Two hundred and thirty-nine patients were treated according to local label with at least one dose of venetoclax. Patient demographics, baseline characteristics, and blood chemistry at baseline were documented, and descriptive statistical analyses were conducted. Seventy eight patients (33%) were treated with venetoclax monotherapy, 101 (42%) with venetoclax in combination with rituximab and 60 (25%) with venetoclax in combination with obinutuzumab. In all cases, the TLS risk mitigation strategy adhered to the ramp-up protocol. Median age was 73 years and 66% of patients were male. The majority of patients (75%) had relapsed/refractory CLL, 63/192 (32.8%) patients tested had a del(17p) and 93/134 (69.4%) patients tested had unmutated immunoglobulin heavy chain variable region gene (IGHV). Clinical TLS occurred in 5 patients (2.1%) and laboratory TLS occurred in 15 patients (6.3%). Ten patients received specific treatment, of which 6 were hospitalized. There were no deaths due to a TLS event and venetoclax was well-tolerated. Of the 5 clinical TLS events reported, none were fatal or resulted in renal failure (NCT03342144, registered on Nov 10, 2017).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Onkologische Schwerpunktpraxis Kurfuerstendamm, Kurfuerstendamm 65, 10707, Berlin, Germany. ingo.schwaner@onkologie-kurfuerstendamm.de.
- AbbVie Deutschland GmbH & Co. KG, Hämatologie, Wiesbaden, Germany.
- Rheinlandklinikum Grevenbroich, Grevenbroich, Germany.
- Onkologie Lerchenfeld, Hamburg, Germany.
- Onkologische Praxis Oldenburg, Oldenburg, Germany.
- Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany.
Förderung
- AbbVie Deutschland
Zitieren
APA
Schwaner, I., Kuhn, T., Losem, C., Wolff, T., Otremba, B., Zaiss, M., Hülsenbeck, J., Famulla, K., Nösslinger, T., & Rossi, D. (2024). Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05638-7
Vancouver
Schwaner I, Kuhn T, Losem C, Wolff T, Otremba B, Zaiss M, et al. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05638-7
BibTeX
@article{Schwaner2024,
author = {Schwaner, Ingo and Kuhn, Thomas and Losem, Christoph and Wolff, Thomas and Otremba, Burkhard and Zaiss, Matthias and Hülsenbeck, Johannes and Famulla, Kirsten and Nösslinger, Thomas and Rossi, Davide},
title = {Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05638-7}
}
EUVIMED